Connection

Patrick O'Neil to Weight Loss

Back to Details
This is a "connection" page, showing publications Patrick O'Neil has written about Weight Loss.
Patrick O'Neil
Connection Strength
7.336
Weight Loss
  1. Long-term maintenance of weight loss. Lancet Public Health. 2022 10; 7(10):e806-e807.
    View in: PubMed
    Score: 0.696
  2. Pilot evaluation of a personalized commercial program on weight loss, health outcomes, and quality of life. Transl Behav Med. 2021 12 14; 11(12):2091-2098.
    View in: PubMed
    Score: 0.658
  3. Changes in weight control behaviors and hedonic hunger in a commercial weight management program adapted for individuals with type 2 diabetes. Int J Obes (Lond). 2020 05; 44(5):990-998.
    View in: PubMed
    Score: 0.577
  4. Body Weight Considerations in the Management of Type 2 Diabetes. Adv Ther. 2019 01; 36(1):44-58.
    View in: PubMed
    Score: 0.532
  5. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018 08 25; 392(10148):637-649.
    View in: PubMed
    Score: 0.523
  6. Characteristics of Weight Loss Trajectories in a Comprehensive Lifestyle Intervention. Obesity (Silver Spring). 2017 12; 25(12):2062-2067.
    View in: PubMed
    Score: 0.495
  7. Effects on cardiovascular risk factors of weight losses limited to 5-10. Transl Behav Med. 2016 09; 6(3):339-46.
    View in: PubMed
    Score: 0.456
  8. EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS. Endocr Pract. 2016 11; 22(11):1277-1287.
    View in: PubMed
    Score: 0.454
  9. Relations of hedonic hunger and behavioral change to weight loss among adults in a behavioral weight loss program utilizing meal-replacement products. Behav Modif. 2013 Nov; 37(6):790-805.
    View in: PubMed
    Score: 0.371
  10. Changes in weight control behaviors and hedonic hunger during a 12-week commercial weight loss program. Eat Behav. 2012 Dec; 13(4):354-60.
    View in: PubMed
    Score: 0.342
  11. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012 Jul; 20(7):1426-36.
    View in: PubMed
    Score: 0.335
  12. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res. 2002 Jul; 10(7):633-41.
    View in: PubMed
    Score: 0.171
  13. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 04 13; 325(14):1403-1413.
    View in: PubMed
    Score: 0.157
  14. The perceived relative worth of reaching and maintaining goal weight. Int J Obes Relat Metab Disord. 2000 Aug; 24(8):1069-76.
    View in: PubMed
    Score: 0.150
  15. Evaluation of a Lifestyle Change Worksite Weight Management Program Across Multiple Employers and Sites. J Occup Environ Med. 2018 12; 60(12):1112-1115.
    View in: PubMed
    Score: 0.133
  16. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab. 2017 11; 19(11):1529-1536.
    View in: PubMed
    Score: 0.121
  17. Impact on psychosocial outcomes of a nationally available weight management program tailored for individuals with type 2 diabetes: Results of a randomized controlled trial. J Diabetes Complications. 2017 May; 31(5):891-897.
    View in: PubMed
    Score: 0.118
  18. Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers. Obesity (Silver Spring). 2016 11; 24(11):2278-2288.
    View in: PubMed
    Score: 0.115
  19. The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy. Int J Obes (Lond). 2016 09; 40(9):1369-75.
    View in: PubMed
    Score: 0.113
  20. Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes. Obesity (Silver Spring). 2014 Oct; 22(10):2137-46.
    View in: PubMed
    Score: 0.098
  21. Changes in cardiovascular risk factors with participation in a 12-week weight loss trial using a commercial format. Eat Behav. 2014 Jan; 15(1):68-71.
    View in: PubMed
    Score: 0.094
  22. Executive control circuitry differentiates degree of success in weight loss following gastric-bypass surgery. Obesity (Silver Spring). 2013 Nov; 21(11):2189-2196.
    View in: PubMed
    Score: 0.094
  23. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011 Jan; 19(1):110-20.
    View in: PubMed
    Score: 0.074
  24. Remission of metabolic syndrome following a 15-week low-calorie lifestyle change program for weight loss. Int J Obes (Lond). 2009 Jan; 33(1):144-50.
    View in: PubMed
    Score: 0.067
  25. Weighing the evidence: benefits of regular weight monitoring for weight control. J Nutr Educ Behav. 2005 Nov-Dec; 37(6):319-22.
    View in: PubMed
    Score: 0.054
  26. Smoking status and weight loss in three weight loss programs. Eat Behav. 2006 Jan; 7(1):61-8.
    View in: PubMed
    Score: 0.053
  27. Utility and validity of the eating behavior inventory in clinical obesity research: a review of the literature. Obes Rev. 2005 Aug; 6(3):209-16.
    View in: PubMed
    Score: 0.053
  28. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022 01 11; 327(2):138-150.
    View in: PubMed
    Score: 0.041
  29. Assessing dietary intake in the management of obesity. Obes Res. 2001 Dec; 9 Suppl 5:361S-366S; discussion 373S-374S.
    View in: PubMed
    Score: 0.041
  30. Pragmatic Weight Management Program for Patients With Obesity and Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc. 2021 11 02; 10(21):e022930.
    View in: PubMed
    Score: 0.041
  31. Cognitive appraisals of dietary transgressions by obese women: associations with self-reported eating behavior, depression, and actual weight loss. Int J Obes Relat Metab Disord. 1999 Mar; 23(3):231-7.
    View in: PubMed
    Score: 0.034
  32. The Food Craving Questionnaire-Trait in a bariatric surgery seeking population and ability to predict post-surgery weight loss at six months. Eat Behav. 2012 Dec; 13(4):366-70.
    View in: PubMed
    Score: 0.021
  33. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring). 2009 Jan; 17(1):30-9.
    View in: PubMed
    Score: 0.017
  34. Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss. Obesity (Silver Spring). 2007 Apr; 15(4):895-905.
    View in: PubMed
    Score: 0.015
  35. Changes in food cravings during low-calorie and very-low-calorie diets. Obesity (Silver Spring). 2006 Jan; 14(1):115-21.
    View in: PubMed
    Score: 0.014
  36. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr. 1999 Jun; 69(6):1108-16.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.